echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > MedAlliance announces completion of Japanese research recruitment

    MedAlliance announces completion of Japanese research recruitment

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Geneva, September 24, 2021/PRNewswire/ - MedAlliance and its Japanese partner MDK Medical have completed the clinical trial of its new sirolimus drug-eluting balloon (DEB) SELUTION SLR™ for the treatment of peripheral arterial disease (PAD) Research recruitment


    MedAlliance announces completion of enrollment in Japanese SELUTION SLR(TM) Study

    The study involved 133 patients in 13 research centers in Japan


    Jeffrey B.


    SELUTION SLR received CE mark approval for the treatment of peripheral artery disease and coronary artery disease in February 2020 and May 2020, respectively


    In August 2021, the first patient out of more than 3,000 patients was recruited into a groundbreaking randomized controlled coronary study that compared SELUTION SLR with Limus drug-eluting stent [DES]


    MedAlliance's DEB technology involves a unique microreservoirs (MicroReservoirs) made of a mixture of biodegradable polymers and anti-restenosis drug Sirolimus


    1.


    About MedAlliance 

    MedAlliance is a private medical technology company


    Source: MedAlliance

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.